News | May 06, 2023
Ajanta pharma posts Q4FY23 consolidated PAT at Rs. 122.25 Cr
The company has reported total income of Rs. 918.67 crores during the period ended March 31, 2023
The company has reported total income of Rs. 918.67 crores during the period ended March 31, 2023
Pheezee is designed to assess musculoskeletal and neuromuscular health.
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
Indoco expects this change in compliance status to pave the way for approvals of ANDAs submitted from this site.
Sun Pharma said had a teleconference call with the US Food and Drug Administration (USFDA) regarding a pulmonary embolism (serious adverse events) occurring at the 12 mg dose
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Subscribe To Our Newsletter & Stay Updated
